Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience

Despite promising findings indicating the therapeutic potential of psychedelic experience across a variety of domains, the mechanisms and factors affecting its efficacy remain unclear. The present paper explores this by focusing on two psychedelic states which have been suggested as therapeutically significant in past literature: ego-dissolution and connectedness. The aim of the study is to investigate the impact of ego-dissolution and connectedness on the therapeutic effects of the psychedelic experience. The investigation was carried out as a mixed methods systematic review, with the data from four databases analysed thematically and results presented through narrative synthesis. The analysis and synthesis of findings from 15 unique studies (n = 2,182) indicated that both ego-dissolution and connectedness are associated with a higher chance of improvement following a psychedelic experience. However, there seem to be differences in the way the two experiences affect individuals psychologically. Ego-dissolution appears to trigger psychological change but does not typically exceed the psychedelic experience in its duration, while connectedness can be more sustained and is associated with several positive, potentially therapeutic feelings. Moreover, the findings of this review have implications for further theory-building about the mechanisms which enable therapeutic effects in psychedelic experience. This in turn might lead to improved models for psychedelic therapy practice. Emphasis on ego-dissolution during the preparation phase and on connectedness during integration is one suggestion presented here, alongside overarching implications for the mental health debate and general practice.

[1]  M. Nour,et al.  The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world , 2022, Psychopharmacology.

[2]  M. Bielecki,et al.  Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences , 2022, Journal of psychopharmacology.

[3]  R. Carhart-Harris,et al.  Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience , 2022, Journal of psychopharmacology.

[4]  Chris Letheby The mechanisms of psychedelic therapy , 2021, Philosophy of Psychedelics.

[5]  J. Woolley,et al.  Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis , 2021 .

[6]  Alan K. Davis,et al.  Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. , 2021, ACS pharmacology & translational science.

[7]  D. E. Olson The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects. , 2020, ACS pharmacology & translational science.

[8]  R. Griffiths,et al.  The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. , 2020, ACS pharmacology & translational science.

[9]  Karen Zilberstein Neoliberalism in clinical social work practice: the benefits and limitations of embedded ideals of individualism and resiliency , 2021 .

[10]  Brian T Anderson,et al.  Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study , 2020, EClinicalMedicine.

[11]  A. Niemeijer,et al.  Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies , 2020, CNS Drugs.

[12]  M. van Elk,et al.  Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism , 2020, Psychopharmacology.

[13]  Chris Letheby,et al.  Psychedelic experience and the narrative self: An exploratory qualitative study , 2020 .

[14]  R. Watts,et al.  The use of the psychological flexibility model to support psychedelic assisted therapy , 2020 .

[15]  S. Hayes,et al.  The centrality of sense of self in psychological flexibility processes: What the neurobiological and psychological correlates of psychedelics suggest , 2020 .

[16]  Alan K. Davis,et al.  Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment , 2019, Psychopharmacology.

[17]  R. Carhart-Harris,et al.  From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner , 2019, International journal of environmental research and public health.

[18]  F. Vollenweider,et al.  Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat , 2019, Scientific Reports.

[19]  E. Argento,et al.  Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada. , 2019, Drug and alcohol review.

[20]  Jacob S. Aday,et al.  2018: A watershed year for psychedelic science , 2019, Drug Science, Policy and Law.

[21]  J. Ramaekers,et al.  A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms , 2019, Psychopharmacology.

[22]  A. Greig,et al.  Towards a Better Understanding of the Relationship between Individual’s Self-Reported Connection to Nature, Personal Well-Being and Environmental Awareness , 2019, Sustainability.

[23]  G. Maruyama,et al.  Replication and extension of a model predicting response to psilocybin , 2019, Psychopharmacology.

[24]  J. Haro,et al.  Act-Belong-Commit Indicators Promote Mental Health and Wellbeing among Irish Older Adults. , 2018, American journal of health behavior.

[25]  N. Broers,et al.  Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution , 2018, Psychopharmacology.

[26]  A. Garcia-Romeu,et al.  Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions , 2018, International review of psychiatry.

[27]  P. Hendricks Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy , 2018, International review of psychiatry.

[28]  Matthew W. Johnson,et al.  Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts , 2018, Journal of psychopharmacology.

[29]  G. Noblit Meta-Ethnography , 2018, Oxford Scholarship Online.

[30]  Elizabeth M. Nielson,et al.  The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions , 2018, Front. Pharmacol..

[31]  Samantha K. Podrebarac,et al.  Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder , 2018, Front. Pharmacol..

[32]  Robin L Carhart-Harris,et al.  Psychedelics and the essential importance of context , 2018, Journal of psychopharmacology.

[33]  David J. Nutt,et al.  Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression , 2018, Front. Pharmacol..

[34]  K. Alper,et al.  Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes , 2018, The American journal of drug and alcohol abuse.

[35]  Frederick S Barrett,et al.  Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. , 2018, Current topics in behavioral neurosciences.

[36]  D. Nutt,et al.  Psilocybin with psychological support for treatment-resistant depression: six-month follow-up , 2017, Psychopharmacology.

[37]  Matthias Forstmann,et al.  Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness , 2017, Journal of psychopharmacology.

[38]  David J. Nutt,et al.  Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression , 2017 .

[39]  Raphaël Millière,et al.  Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution , 2017, Frontiers in human neuroscience.

[40]  H. Friedman,et al.  Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis , 2017 .

[41]  Matthew W. Johnson,et al.  Long-term follow-up of psilocybin-facilitated smoking cessation , 2017, The American journal of drug and alcohol abuse.

[42]  Matthew W. Johnson,et al.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.

[43]  P. Garrett Questioning Tales of ‘Ordinary Magic’: ‘Resilience’ and Neo-Liberal Reasoning , 2016 .

[44]  James Rucker,et al.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. , 2016, The lancet. Psychiatry.

[45]  M. Nour,et al.  Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI) , 2016, Front. Hum. Neurosci..

[46]  Matthew W. Johnson,et al.  Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin , 2015, Journal of psychopharmacology.

[47]  Kate Cavanagh,et al.  How do mindfulness-based cognitive therapy and mindfulness-based stress reduction improve mental health and wellbeing? A systematic review and meta-analysis of mediation studies. , 2015, Clinical psychology review.

[48]  M. Lalayants,et al.  Loneliness and Depression or Depression-Related Factors Among Child Welfare-Involved Adolescent Females , 2015 .

[49]  J. Gallinat,et al.  Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? , 2015, Journal of psychopharmacology.

[50]  R. Strassman,et al.  Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study , 2015, Journal of psychopharmacology.

[51]  Matthew W. Johnson,et al.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction , 2014, Journal of psychopharmacology.

[52]  Peter J Hellyer,et al.  The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs , 2014, Front. Hum. Neurosci..

[53]  Aaron Smith,et al.  6% of online adults are reddit users , 2013 .

[54]  G. Martin,et al.  Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. , 2013, Current drug abuse reviews.

[55]  Matthew W. Johnson,et al.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness , 2011, Journal of psychopharmacology.

[56]  Matthew W. Johnson,et al.  Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects , 2011, Psychopharmacology.

[57]  A. Piper,et al.  A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms?1 , 2011, Economic Botany.

[58]  C. Grob,et al.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. , 2011, Archives of general psychiatry.

[59]  Michael Kometer,et al.  The neurobiology of psychedelic drugs: implications for the treatment of mood disorders , 2010, Nature Reviews Neuroscience.

[60]  F. Vollenweider,et al.  Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV) , 2010, PloS one.

[61]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[62]  S. Krippner,et al.  Changes in Spirituality Among Ayahuasca Ceremony Novice Participants , 2009, Journal of psychoactive drugs.

[63]  E. Goode moral panics and disproportionality: the case of LSD use in the sixties , 2008 .

[64]  R. Griffiths,et al.  Human hallucinogen research: guidelines for safety , 2008, Journal of psychopharmacology.

[65]  R. Griffiths,et al.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance , 2006, Psychopharmacology.

[66]  L. Hawkley,et al.  Loneliness as a specific risk factor for depressive symptoms: cross-sectional and longitudinal analyses. , 2006, Psychology and aging.

[67]  S. Peroutka,et al.  Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex , 2004, Psychopharmacology.

[68]  Nilly Mor,et al.  Self-focused attention and negative affect: a meta-analysis. , 2002, Psychological bulletin.

[69]  N. Goodman The Serotonergic System and Mysticism: Could LSD and the Nondrug-Induced Mystical Experience Share Common Neural Mechanisms? , 2002, Journal of psychoactive drugs.

[70]  A Dittrich,et al.  The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans , 1998, Pharmacopsychiatry.

[71]  R A Williams,et al.  Sense of belonging and indicators of social and psychological functioning. , 1996, Archives of psychiatric nursing.

[72]  I. Åkerlind,et al.  Loneliness and alcohol abuse: a review of evidences of an interplay. , 1992, Social science & medicine.

[73]  R. Glennon,et al.  Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. , 1984, Life sciences.

[74]  R. Mogar,et al.  Peak Experiences: Investigation of Their Relationship to Psychedelic Therapy and Self-Actualization , 1967 .

[75]  G. H. Litwin,et al.  REACTIONS TO PSILOCYBJN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT , 1963, The Journal of nervous and mental disease.